New trial designs and potential therapies for pulmonary artery hypertension.

[1]  G. Stone,et al.  TCT-683 Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study , 2013 .

[2]  G. Stone,et al.  Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). , 2013, Journal of the American College of Cardiology.

[3]  H. Ghofrani,et al.  Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.

[4]  S. Archer,et al.  Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension , 2013, Pulmonary circulation.

[5]  S. Said.  Vasoactive intestinal peptide in pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[6]  M. Humbert,et al.  Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[7]  T. Fleming,et al.  Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.

[8]  M. Böhm,et al.  Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.

[9]  T. Welte,et al.  Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. , 2012, American journal of respiratory and critical care medicine.

[10]  J. Loscalzo,et al.  Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension , 2012, Circulation.

[11]  D. Stewart,et al.  Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. , 2012, The American journal of cardiology.

[12]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[13]  D. Brodie,et al.  Venovenous extracorporeal membrane oxygenation using a single cannula in patients with pulmonary hypertension and atrial septal defects. , 2012, The Journal of thoracic and cardiovascular surgery.

[14]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[15]  H. Tan,et al.  Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  N. Leidy,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Elizabeth Molsen,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  S. Keshavjee,et al.  Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  S. Archer,et al.  Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle , 2011, Journal of Molecular Medicine.

[20]  Katherine Odem-Davis,et al.  Some essential considerations in the design and conduct of non-inferiority trials , 2011, Clinical trials.

[21]  D. Brodie,et al.  Use of bicaval dual-lumen catheter for adult venovenous extracorporeal membrane oxygenation. , 2011, The Annals of thoracic surgery.

[22]  H. Ghofrani,et al.  Targeting non-malignant disorders with tyrosine kinase inhibitors , 2010, Nature Reviews Drug Discovery.

[23]  N. Voelkel,et al.  Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. , 2010, American journal of respiratory and critical care medicine.

[24]  T. Welte,et al.  Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  L. Rubin,et al.  Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  H. Farber,et al.  Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[28]  J. Barberà,et al.  Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH) , 2010, ATS 2010.

[29]  B. Hasinoff.  The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. , 2010, Toxicology and applied pharmacology.

[30]  M. Maitland,et al.  A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension , 2010, Clinical pharmacology and therapeutics.

[31]  K. Coombes,et al.  Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. , 2010, The Journal of clinical investigation.

[32]  F. Grimminger,et al.  PDGF receptor and its antagonists: role in treatment of PAH. , 2010, Advances in experimental medicine and biology.

[33]  M. Humbert,et al.  Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α‐targeted overexpression of the serotonin transporter , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Theo Arts,et al.  Right ventricular free wall pacing improves cardiac pump function in severe pulmonary arterial hypertension: a computer simulation analysis. , 2009, American journal of physiology. Heart and circulatory physiology.

[35]  A. Malik,et al.  Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.

[36]  N. Weissmann,et al.  Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[37]  E. Braunwald,et al.  Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. , 2009, Journal of the American College of Cardiology.

[38]  T. Welte,et al.  Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Behr,et al.  Inhalation of vasoactive intestinal peptide in pulmonary hypertension , 2008, European Respiratory Journal.

[41]  S. Srinivas,et al.  Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  M. Gomberg-Maitland.  Traditional and alternative designs for pulmonary arterial hypertension trials. , 2008, Proceedings of the American Thoracic Society.

[43]  P. Hassoun,et al.  Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[44]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[45]  J. Zwanenburg,et al.  Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. , 2008, Journal of the American College of Cardiology.

[46]  Thomas R Fleming,et al.  Current issues in non‐inferiority trials , 2008, Statistics in medicine.

[47]  P. McNamara,et al.  Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[48]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[49]  M. Humbert,et al.  Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension , 2007, European Respiratory Journal.

[50]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[51]  Y. Shang,et al.  Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. , 2007, Journal of the American College of Cardiology.

[52]  Michael L Maitland,et al.  Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets , 2006, Annals of Internal Medicine.

[53]  A. Yao,et al.  Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[54]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[55]  S. Goldsmith.  Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure. , 2006, Cleveland Clinic journal of medicine.

[56]  P. Pacaud,et al.  Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.

[57]  M. Humbert,et al.  Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.

[58]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[59]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[60]  H. Shimokawa,et al.  Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.

[61]  P. Rycus,et al.  Extracorporeal Life Support Registry Report 2004 , 2005, ASAIO journal.

[62]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[63]  K. Morris,et al.  Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[64]  R. Naeije,et al.  Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension , 2004, Circulation.

[65]  K. Kaibuchi,et al.  Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.

[66]  G. Berry,et al.  Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.

[67]  J. Halperin,et al.  Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. , 2003, American heart journal.

[68]  G. Funk,et al.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.

[69]  Benoît Rondelet,et al.  Single-beat estimation of right ventricular end-systolic pressure-volume relationship. , 2003, American journal of physiology. Heart and circulatory physiology.

[70]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  T. Giles,et al.  Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[73]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[74]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  Y. Takanashi,et al.  The Effects of Vasoactive Intestinal Peptide on Monocrotaline Induced Pulmonary Hypertensive Rabbits following Cardiopulmonary Bypass: A Comparative Study with Isoproteronol and Nitroglycerine , 2002, Cardiovascular surgery.

[76]  R. Schilsky.  End points in cancer clinical trials and the drug approval process. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[78]  J. Dyck,et al.  Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.

[79]  M. Humbert,et al.  CX(3)C chemokine fractalkine in pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[80]  Liang Li,et al.  Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. , 2001, American journal of respiratory cell and molecular biology.

[81]  N. Voelkel,et al.  Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis , 2001, Circulation research.

[82]  P. Huang,et al.  Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[83]  J. Parrillo,et al.  Cytoplasmic redox potential affects energetics and contractile reactivity of vascular smooth muscle. , 1997, Journal of molecular and cellular cardiology.

[84]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[85]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[86]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[87]  P. Ganz,et al.  Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. , 1996, Circulation.

[88]  J. Mccormack,et al.  Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.

[89]  S. Said,et al.  VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. , 1995, The American journal of physiology.

[90]  Jesse D. Roberts,et al.  Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. , 1995, Circulation research.

[91]  N. Voelkel,et al.  Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. , 1994, American journal of respiratory cell and molecular biology.

[92]  S. Pocock,et al.  Factorial trials in cardiology: pros and cons. , 1994, European heart journal.

[93]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[94]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[95]  R. Rossaint,et al.  Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells. , 1993, European heart journal.

[96]  M. Abrahamowicz,et al.  Randomized discontinuation trials: utility and efficiency. , 1993, Journal of clinical epidemiology.

[97]  R. Rossaint,et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, The New England journal of medicine.

[98]  S. Abman,et al.  Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.

[99]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[100]  P. Stacpoole.  The pharmacology of dichloroacetate. , 1989, Metabolism: clinical and experimental.